Suraksha Diagnostic Ltd IPO

Suraksha Diagnostic Ltd IPO

Healthcare

mainboard

Bidding period

29 Nov 2024 - 03 Dec 2024

Bid price

₹441.00 - ₹441.00

Listing on

BSE, NSE

Listing date

06 Dec 2024

Lot size

34 shares

Issue size

₹846.25 crore


Minimum investment

₹14,994.00 / 1 lot

Maximum investment

₹1,94,922.00 / 13 lot

Bidding closed on 03 Dec 2024

EXPLORE IPOs
EXPLORE IPOs

Suraksha Diagnostic Ltd IPO dates

IPO opening date

29 Nov 2024

IPO end date

03 Dec 2024

Allotment date

04 Dec 2024

Initiation of refunds

05 Dec 2024

Credit of shares to demat

05 Dec 2024

IPO listing date

06 Dec 2024

Suraksha Diagnostic Ltd IPO financials

Particulars

For the period ending in March 2024 (in ₹ million)

Total assets ₹300.20
Total liabilities ₹300.20
Total expenditure ₹190.03
Total revenue ₹222.26
Profit after tax ₹23.63
EBITDA ₹72.84
Adjusted EBITDA ₹0.00

Suraksha Diagnostic Ltd shareholder pattern

Pre-issue Post-issue
Promoter group 61.07 48.78
Public group 38.93 51.22

Suraksha Diagnostic Ltd strengths and risks

Information currently unavailable

  • Diagnostic chain with in eastern India well positioned to leverage growth opportunity for organized diagnostic chains in the diagnostic services markets in eastern and north-eastern India.

  • Track record of profitability and financial performance.

  • Integrated diagnostics provider with one-stop solution offering pathology and radiology testing, and medical consultation services.

  • Technologically advanced clinical infrastructure and trained personnel providing diagnostic services.

  • Commitment to quality driving high individual consumer business share and customer retention.

  • Management team with relevant industry experience.

  • 95.48% of its Revenue from Operations in Fiscal 2024 was generated from West Bengal, and any loss of business in such region could have an adverse effect on its business, results of operations and financial condition.

  • The securities of certain of its Promoter Group members have been suspended from trading on a recognized stock exchange in the past. The company cannot assure you that there will be no such instances in the future which may adversely affect its operations, reputation and ability to raise capital through further public issue of securities.

  • The diagnostics industry in India is highly competitive and its inability to compete effectively from other healthcare service providers may adversely affect its business, results of operations and financial condition. Further, as of Financial Year 2024, the market share of the Company in its major market which is East India is 1.15-1.30%.

  • The B2B segment contributed to 6.17% of its Revenue from Operations in Fiscal 2024 and any non-renewal or cancellation of its arrangements with its institutional customers, including hospitals, and Public-Private Partnership ("PPP") contracts may adversely affect its business, results of operations and financial condition.

  • Its Statutory Auditors have included certain emphasis of matters, and audit qualifications matters prescribed in the audit reports of the Company for Fiscals 2023 and 2024.

  • In the past, the company failed to comply with certain provisions of the Companies Act, 2013, and had to compound such non-compliances. The company cannot assure you that there will be no such non-compliances in the future and that the Company, Promoters, or Directors will not be subject to any penalty or additional payment.

  • Certain of its Promoters, Directors, Subsidiaries and Group Company are in businesses similar to its and have interests in certain companies, which are in similar businesses to its, and this may result in potential conflict of interest with the company.

  • Its Promoters and certain members of the company Promoter Group pledged some of the Equity Shares held by them in favour of Vistra ITCL (India) Limited, in its capacity as debenture trustee for the benefit of the debentureholders, as security for debentures issued by its Promoter Group entity, Tinni Investments Limited, and there are disposal restrictions created on Equity Shares held by certain other shareholders. Upon creation, any invocation of such pledge could dilute the aggregate shareholding of its Promoters, and such members of the company Promoter Group, which may cause a change in control of the Company and trigger an open offer requirement under the Takeover Regulations.

  • There are outstanding legal proceedings involving the Company, Subsidiaries, Promoters, Directors and Group Companies which may adversely affect its business, financial condition and results of operations.

  • The Company will not receive any proceeds from the Offer for Sale. The Selling Shareholders will receive the entire net proceeds from the Offer for Sale.

How to check the allotment status of the Suraksha Diagnostic Ltd IPO?

To check the IPO allotment status, follow these steps:

 

  1. Visit the official website of the IPO’s registrar.
  2. Go to the IPO allotment status page.
  3. Select the ‘Suraksha Diagnostic Ltd’ from the list of available IPOs.
  4. Enter your PAN, Demat ID, or application number.
  5. Click on ‘Submit’ or ‘Check Status’ to view your allotment details.

Alternatively, you can also check the allotment status on stock exchange websites such as the NSE or BSE.

To check the IPO allotment status, follow these steps:

 

  1. Visit the official website of the IPO’s registrar.
  2. Go to the IPO allotment status page.
  3. Select the ‘Suraksha Diagnostic Ltd’ from the list of available IPOs.
  4. Enter your PAN, Demat ID, or application number.
  5. Click on ‘Submit’ or ‘Check Status’ to view your allotment details.

Alternatively, you can also check the allotment status on stock exchange websites such as the NSE or BSE.

Read more Read less

Suraksha Diagnostic Ltd IPO registrar

KFin Techologies Ltd

Phone number +91 40 6716 2222
E-mail ID einward.ris@kfintech.com
Website www.kfintech.com

Suraksha Diagnostic Ltd IPO reservation

QIB shares offered

38,37,866 (20.0%)

NII (HNI) shares offered

28,78,400 (15.0%)

Retail shares offered

67,16,265 (35.0%)

Anchor investor shares offered

57,56,799 (30.0%)

Total shares offered

1,91,89,330

Total shares with anchor investor

1,91,89,330

Suraksha Diagnostic Ltd IPO lead manager

  • ICICI Securities Ltd
  • Nuvama Wealth Management Ltd
  • SBI Capital Markets Ltd

Explore other IPOs

How to apply for an IPO with Bajaj Broking?

adafafds
 
 
  • Log in to the Bajaj Broking trading platform and select ‘IPO’ from the menu.
  • Browse the list of open IPOs and click ‘Apply’ for your chosen IPO.
  • Enter the quantity and your UPI ID.
  • Submit your application—and you're done!

Frequently asked questions

What is the listing date for the Suraksha Diagnostic Ltd IPO?

The listing date for the Suraksha Diagnostic Ltd IPO is 06 Dec 2024.

What is the issue size of Suraksha Diagnostic Ltd IPO?

The issue size of the Suraksha Diagnostic Ltd IPO is ₹846.25 cr.

What is the minimum lot size needed for Suraksha Diagnostic Ltd IPO?

The minimum lot size for Suraksha Diagnostic Ltd IPO is 34

When does the Suraksha Diagnostic Ltd open and close?

Suraksha Diagnostic Ltd IPO is open from 29 Nov 2024 to 03 Dec 2024.

How can I apply for the Suraksha Diagnostic Ltd IPO?

To apply for the Suraksha Diagnostic Ltd, follow the steps given below:

  • Log in to your Bajaj Broking trading account and navigate to the current IPOs section.
  • Browse the list of open IPOs and click ‘Apply’ for your chosen PO.
  • Enter the quantity and your UPI ID. You will receive a mandate notification to block funds in your UPI app.
SHOW MORE SHOW LESS

Disclaimer

*Disclaimer for Bajaj Finance Limited (‘BFL’):

Stock trading business is carried by Bajaj Financial Securities Limited ("BFSL"), a broker and Depository Participant registered with Securities Exchange Board of India and offers various products/services related to Securities market (Securities market products/services). BFL merely facilitates display of data shared by BFSL on its webpage/mobile application. Such data received from BFSL, or any of its service providers is on “as is” basis. BFL does not make any representation or warranty, express or implied, regarding accuracy, completeness of such data displayed herein.

When you opt to avail the Securities market products/services of BFSL by clicking on the BFSL weblink/mobile app, you will be redirected to BFSL's web page/mobile app for initiation and completion of the transaction. You are supposed to exercise independent diligence by reading all the related documents carefully before deciding to invest in Securities market Products/services.

BFL is a Non-Banking Financial Company carrying the business of acceptance of deposits and providing lending solutions to Retail and Corporate customers. BFL does not offer nor advice on Securities market products/services and shall not be liable or responsible for any of your investment decision."

**Disclaimer: For Bajaj Financial Securities Limited

Investments in securities market are subject to market risk, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit. All leveraged intraday positions will be squared off the same day. There is no restriction on withdrawal of unutilised margin amount. Trade Recommendations are research-calls provided under the SEBI Research Analyst guidelines.
Visit https://www.bajajbroking.in/disclaimer for complete disclaimer.

Securities market Products/services are made available only at the discretion of BFSL and subject to the individual contractual terms and conditions of the respective Securities market products/services. You shall be the sole owner of any decision to invest in any BFSL's Securities market products/services.

Securities market products/services may be withdrawn or amended at any time by BFSL without notice and your recourse in such case would be directly to reach out BFSL at connect@bajajfinserv.in or 1800 833 8888.

Powered by Bajaj Financial Securities Limited (Bajaj Broking)